
==== Front
J Res Health Sci
J Res Health Sci
J Res Health Sci
JRHS
Journal of Research in Health Sciences
2228-7795
2228-7809
Hamadan University of Medical Sciences

10.34172/jrhs.2024.153
Review Article
Retention in Care Among People Living with HIV in Nigeria: A Systematic Review and Meta-analysis
https://orcid.org/0000-0001-6732-1042
Olawepo John O. 1 2 *
https://orcid.org/0009-0004-7556-0034
O'Brien Katherine 1
Papasodoro Julia 1
Coombs Philip E. 3
Singh Neha 1
Gupta Shubhi 4
Bhan Aarushi 5
Olakunde Babayemi O. 2 6
Ezeanolue Echezona E. 2 7
1Department of Health Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, USA
2Center for Translation and Implementation Research (CTAIR), University of Nigeria, Enugu, Nigeria
3Department of Research and Instruction, Northeastern University Library, Northeastern University, Boston, USA
4Department of Health Informatics, Khoury College of Computer Science, Bouvé College of Health Sciences, Northeastern University, Boston, USA
5Department of Biology, College of Science, Northeastern University, Boston, MA, USA
6Department of Population and Community Health, University of North Texas Health Science Center, Fort Worth, Texas, USA
7Healthy Sunrise Foundation, Las Vegas, Nevada, USA
* Corresponding author: John O. Olawepo, Email: j.olawepo@northeastern.edu
Summer 2024
31 7 2024
24 3 e00618e00618
12 2 2024
18 3 2024
06 4 2024
© 2024 The Author(s); Published by Hamadan University of Medical Sciences.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://jrhs.umsha.ac.ir
Background: In 2021, Nigeria had an estimated 1.9 million people living with the human immunodeficiency virus (PLHIV) and 1.7 million (90%) on antiretroviral therapy (ART).

Study Design: A systematic review and meta-analysis.

Methods: This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines. We searched PubMed, Embase, PsychINFO, CINAHL, Global Index Medicus, and Cochrane Library. Studies were included if they reported on ART retention in care among PLHIV in Nigeria. The random-effects meta-analyses were used to combine the studies that had complete retention data. The I2 statistic was used to assess the heterogeneity of the studies. A sensitivity analysis was then done by conducting a leave-one-out analysis. Afterward, data were analyzed using STATA version 18.

Results: The search yielded 966 unique articles, of which 52 studies met the inclusion criteria for the meta-analysis, and four experimental studies were split into their component arms. The total number of study participants was 563,410, and the pooled retention rate was 72% (95% CI: 67%, 76%; I2=99.9%; n=57). Sub-analysis showed that the Southeast region of Nigeria had the highest retention of 86% (95% CI: 78%, 92%), and the South-South had the lowest retention (58%; 95% CI: 38%, 79%).

Conclusion: In Nigeria, the pooled ART retention rate is less than optimal to achieve the UNAIDS goal of 95%, thus developing new models for ART retention is needed.

Retention in care
Nigeria
Antiretroviral agents
Meta-analysis
Please cite this article as follows: Olawepo JO, O’Brien K, Papasodoro J, Coombs PE, Singh N, Gupta S, et al. Retention in care among people living with HIV in Nigeria: a systematic review and meta-analysis. J Res Health Sci. 2024; 24(3):e00618. doi:10.34172/jrhs.2024.153
==== Body
pmcBackground

Human immunodeficiency virus (HIV) is a complex disease that has led to significant morbidity and mortality since it was first identified in the 1980s.1 In 2021, 38.4 million adults and children globally were living with HIV, with 1.5 million of those individuals newly infected.2 Sub-Saharan Africa bears the highest burden with 51% of new HIV infections occurring in the region.2 Nigeria, Africa’s most populous country, had 1.9 million adults and children living with HIV in 2021, with an adult prevalence rate of 1.3%.3 Seventy-four thousand (74 000) new infections occurred in 2021, along with 51 000 deaths. Since 2010, new HIV infections in Nigeria have decreased by 39% which is less than the global average decrease.3

Antiretroviral therapy (ART) is the mainstay of HIV treatment, and it prevents transmission by reducing the viral load of the infected individual to very low levels.4 Globally, around 85% of people living with HIV (PLHIV) are aware of their status, and 75% of PLHIV are adhering to ART.2 In Nigeria, 90% of PLHIV are on ART, and more adult women (97%) are receiving ART than adult men (94%) and children (31%). Moreover, 34% of pregnant women receive treatment for the prevention of mother-to-child transmission of HIV (PMTCT).3 Nigeria implements a “test and treat” policy, where all HIV-positive persons are eligible to receive ART, regardless of their CD4 + cell count. Although evidence suggests that most PLHIV will achieve viral load suppression within 6 months of ART initiation,5,6 it is unknown what proportion of PLHIV in Nigeria is retained on treatment long enough to attain and maintain viral suppression.

Numerous studies have documented the importance of retention in HIV care for both viral suppression and mortality.7-9 Retention in care has contributed to averting mortality rates and has been linked to better health outcomes and safer sexual behaviors.7,10 However, there is no clear gold standard definition of retention, and the choice of retention metric is contextual. Retention is complex, challenging to define, and hard to measure.11 It is defined differently across various agencies. The Centers for Disease Control and Prevention (CDC) defines retention as two viral load tests or CD4 cell counts completed more than 3 months apart.12 In contrast, the World Health Organization (WHO) defines retention more loosely as the routine attendance of services such as clinic appointments and taking medication as per the patient’s needs.13 Likewise, the Health Resources Service Administration (HRSA) and Institute of Medicine (IOM) provide different definitions: two medical visits at least 90 days apart and at least two medical visits per 12 months, respectively.12

Several studies have reported retention in care among PLHIV in Nigeria, but the differing definitions have created a knowledge gap about the true proportion of PLHIV retained on ART in Nigeria. Accordingly, this systematic review and meta-analysis strived to provide a pooled estimate of ART retention in Nigeria based on the literature published on this topic to better inform retention programs in the future.

Methods

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 reporting guidelines.14 The review protocol was registered in PROSPERO on March 8, 2022.15 Searches were constructed by a librarian (PEC) with expertise in health sciences systematic reviews in September 2021. The following databases were subsequently searched: PubMed (Supplementary file 1, Table S1), Embase via Embase.com, PsycINFO (via EBSCO), CINAHL (via EBSCO), Global Index Medicus, and the Cochrane Library. Full search strings for each database are accessible at Northeastern University Library’s Digital Repository Service (https://repository.library.northeastern.edu/files/neu:0v838204v).16

Inclusion and exclusion criteria

Eligibility criteria included studies with outcomes relating to retention in care for PLHIV who are on ART in Nigeria. Studies were excluded if they were not conducted in Nigeria, the population was not on ART, or there were no reported outcomes relating to retention in care. In addition, there were no restrictions on the publication date or study design, and eligible studies were limited to those published in the English language.

Data collection and extraction

The systematic review screening software Rayyan17 was used to deduplicate results. A dual-blinded screening was conducted using Rayyan at both title/abstract (JP and KO) and full-text stages (KO and JP). Conflicts were resolved through team discussion and consensus (JOO, JP, and KO), and data extraction was conducted by four reviewers (JOO, JP, KO, and SG). The extracted information included first author, title, journal, year of publication, study design, study population, geopolitical region where the study was conducted, number of study participants (specifying arm, if randomized trial), age of participants (mean, median, and/or range), duration of study (year - year), follow-up time, number of retained participants, and retained proportion. Three reviewers (JP, KO, and SG) split up the articles equally and extracted data from each paper. The data were subsequently reviewed and organized (by JOO). In instances in which retention was measured multiple times during a study, we used the last (most recent) measurement.In addition, some of the studies did not state the number of people or proportion retained. Some of the studies provided figures for those lost to follow-up (LTFU), and these figures were extrapolated to compute the number retained on ART. For the age categorization, we aligned our analysis based on how the eligible studies categorized their participants, that is, participants ≤ 14 years were categorized as children, those aged 15-17 were adolescents, those aged 18-24 were young adults, and individuals aged 18-65 + were categorized as adults.

Quality review

Included studies were assessed for risk of bias using the Effective Public Health Practice Project (EPHPP) quality assessment tool for quantitative studies.18 Articles were evaluated and rated strong, moderate, or weak based on selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts. A global rating was then assigned based on the criteria outlined in the EPHPP. Subsequently, articles received a global rating as good if there were no individual weak ratings in any category or moderate if there was only one weak rating in any individual category. The included articles were independently screened for quality assessment by two reviewers (JP and KO), and disagreements were resolved through discussion with JOO for the team to reach a consensus.

Statistical analysis

The eligible articles were examined for summary statistical measures, primarily the proportion of PLHIV retained on ART. Only the studies that had the number retained (numerator) and the base population on ART (denominator) were included in the meta-analysis. Due to the widely varying nature of the studies, random effects meta-analyses were used to combine all the eligible studies. Experimental studies where participants had different exposure or intervention arms were split into their component arms for ease of the meta-analysis. Egger’s regression test was performed for asymmetry in the funnel plot for publication bias. The I2 statistic was used to assess the heterogeneity of the studies. A pooled effect size based on the individual effect sizes and their sampling variances was computed using the DerSimonian-Laird between-study variance estimators. We assessed influential cases/outliers to see if the pooled effect estimate we found was robust. A Baujat plot was used to detect studies that overly contributed to the heterogeneity in the meta-analysis. We also conducted a moderator analysis (Subgroup analysis). Sensitivity analysis was performed using a leave-one-out analysis. Sub-analyses were performed by age categories, geographical regions of Nigeria, participant follow-up time, and year of publication. Data were analyzed using STATA version 18.0.

Results

Search results

The initial search of the literature yielded 1,494 articles, of which 528 duplicate articles were removed through Rayyan.17 The remaining 966 articles were dually screened by abstract and titles, with 114 articles approved for full-text screening. Accordingly, 54 studies were included for the qualitative synthesis, and 52 for the meta-analytic synthesis (Supplementary file 1, Table S2)19-72 Sixty articles were excluded for the following reasons: wrong outcome (n = 22), some or all participants not on ART (n = 16), no retention data (n = 10), not specific to Nigeria (n = 6), study has not yet begun (n = 4), abstract only (n = 1), and reports on the same study population (n = 1) (see Figure 1 for the PRISMA Flow Diagram).

Figure 1 PRISMA flow diagram. Note. PRISMA: Preferred reporting items for systematic reviews and meta-analyses

Description of included studies and qualitative synthesis

The 54 eligible studies were published between 2005 and 2021. Seventeen studies were conducted across multiple states not enclosed within a specific geographical region in Nigeria, followed by 15 studies within states in the North-Central region. There were no identified studies conducted solely within states in the North-East region of Nigeria (Figure 2). Most of the studies were retrospective cohorts (n = 36, 67%), followed by prospective cohorts (n = 6, 11%), mixed designs (n = 5, 9%), quasi-experimental designs (n = 4, 7%), and randomized trials (n = 3, 6%). The total number of study participants from the 54 studies was 563 410. Furthermore, eight studies had more than 10 000 participants, but most of the studies (n = 20) had between 1000 and 10 000 participants. The follow up time of the studies ranged from 6 months to 14 years.

Figure 2 Number of studies by geopolitical zones

Overall, we identified multiple definitions of retention among the eligible studies. For example, some authors defined retention as “being in care if the time between any two consecutive visits was ≤ 90 days and the time between the last visit and censor date was ≤ 180 days.”23,24 Others defined retention as “the number of people known to be alive and on ART 12 months after starting ART, including those who interrupted care (missed one or two appointments or drug pick-ups.)”34 Some authors further categorized their definition on how good or adequate the retention was. For example, “participants with a total of four visits (over 12 months) were categorized as having adequate retention while those who made less than four visits were categorized as having inadequate retention,”38 or “participants who visited the hospital and received ART refill at least once in each quarter for all the four quarters were classified as having good retention. Otherwise, they were classified as having poor retention.”72 Other authors also defined retention as “being alive and still on ART at the time of last appointment,”42,63,68 as “not having missed a scheduled appointment by more than 28 days,”45 as 2 HIV care-related visits to the clinic in each 24-week observation period,”69 or “having one or more clinic visits in the one year review period.”71

Some contextual definitions were also identified. For example, in a differentiated care delivery model, retention was defined as “any stable ART patient who remained within their Community Anti-retroviral Groups (without default in routine clinic visits) at the end of the one-year follow-up period.”41 Additionally, in the eligible studies conducted in PMTCT settings, participants were defined as “fully retained-in-care at 6 months postpartum if the woman attended the 6-month postpartum visit (630 days) and did not miss any previous scheduled visit by more than 30 days (starting from ANC booking) or partially retained-in-care at 6 months postpartum if the woman attended the 6-month postpartum visit (630 days) but missed one or more earlier scheduled visits by more than 30 days.”64 Another study on PMTCT also defined maternal retention as “...by clinic attendance during the first 6-month postpartum. Participants with ≥ 3 of 6 expected monthly visits were considered retained.”65,67

Risk of bias and rating of study quality

Using the EPHPP tool, the quality assessment showed that 40.7% (n = 22) of studies had moderate rating, 38.9% (n = 21) of studies had strong rating, and 20.4% (n = 11) of them had weak rating. Full results are available in Supplementary file 1 (Table S3).

Meta-analysis results

Fifty-two studies were included in the meta-analysis. Two out of the 54 studies were excluded from the meta-analysis because they only provided retention rates but no data on the number of patients retained.27,42 The pooled retention rate was 72% (95% confidence interval [CI]: 67,76; I2 = 99.9%; n = 57), as depicted in Figure 3, and retention ranged from 36.4% to 100%. There was no significant difference in proportion retained across publication years, age categories, region, or participant follow-up time. The Egger’s test (standard error = 1.27, z = 0.40, P = 0.6884) showed evidence of small-study effects (see funnel plot in Figure 4). Moreover, all the overall effect sizes from the leave-one-out analysis were close to the overall effect-size, and their confidence interval lines intersected with the overall effect size. This means that there are no studies that substantially influence the results of our meta-analysis (Figure 5).

Figure 3 Forest plot for all included studies

Figure 4 Funnel plot for included studies

Figure 5 Sensitivity analysis results

Exploratory subgroup analysis

Since heterogeneity between studies was 99.9%, we performed subgroup analysis by looking for between-study variance for such variables as age, year of publication, the geographic region in Nigeria, and participant follow-up time. Geographic region and participant follow-up time indicated a moderating effect. For age categorization, studies including adolescents and adults (n = 14) had a pooled retention rate of 71%, while those including adults only (n = 32) had a pooled retention rate of 72%. There were no eligible studies with only adolescents or children. Concerning the geographical regions, studies from the Southeast region (n = 5) had the highest pooled retention rate of 86%, while studies from the South-South region (n = 3) had a pooled retention rate of 58%. For participant follow-up time, the highest pooled retention rate was among studies with a follow-up time of 6-12 months (75%; n = 28), while the lowest pooled retention rate was among studies with a follow-up time of > 24-48 months (65%; n = 3). For the year of publication, studies published between 2011 and 2015 (n = 26) had the highest pooled retention at 73%. A summary of these retention rates and sub-analyses can be found in Table 1.

Table 1 Exploratory Subgroup Analyses Results

Category	Studies	Effect size (95% CI)	I2	P value	
Age group					
Adolescents and adults	14	0.71 (0.63, 0.80)	99.8%	 < 0.001	
Adolescents, children, and young adults	8	0.70 (0.59, 0.82)	99.6%	 < 0.001	
Adults only	32	0.72 (0.66, 0.78)	99.8%	 < 0.001	
All age groups	3	0.72 (0.57, 0.87)	99.9%	 < 0.001	
Geographical region					
North-Central	15	0.74 (0.65, 0.83)	99.8%	 < 0.001	
North-West	7	0.67 (0.57, 0.78)	99.3%	 < 0.001	
South-East	5	0.86 (0.78, 0.92)	98.0%	 < 0.001	
South-South	3	0.58 (0.38, 0.79)	96.1%	 < 0.001	
South-West	9	0.75 (0.64, 0.85)	98.7%	 < 0.001	
Multiple states/regions	18	0.67 (0.60, 0.75)	99.9%	 < 0.001	
Participant follow-up time (month)					
6-12	28	0.75 (0.69, 0.81)	99.3%	 < 0.001	
 > 12-24	13	0.66 (0.57, 0.75)	99.9%	 < 0.001	
 > 24-48	3	0.65 (0.39, 0.90)	100%	 < 0.001	
 > 48	12	0.70 (0.62, 0.78)	99.8%	 < 0.001	
Year of publication					
2005-2010	4	0.62 (0.39, 0.86)	98.5%	 < 0.001	
2011-2015	26	0.73 (0.68, 0.79)	99.7%	 < 0.001	
2016-2021	27	0.71 (0.64, 0.78)	99.9%	 < 0.001	

Discussion

The main finding from the current study is that from the eligible studies published between 2005-2021, the pooled retention rate for PLHIV on ART in Nigeria is 72%, which is less than optimal to achieve the UNAIDS 95-95-95 goals.73 Simply starting treatment does not guarantee viral suppression, and retention in care is a critical bridge between the second 95 and the third 95 of the UNAIDS goals.74,75 When retention is less than optimal, the benefits of ART become less attainable at the population level, and patients are at a higher risk for treatment failure, drug resistance, and death. If a considerable proportion of PLHIV on ART are not actively and continuously engaged in treatment, new HIV infections will continue to occur, further hampering the move towards zero HIV transmission.76

Our findings align with previous studies that estimated 77%, 75%, and 75% retention rates at 6, 12, and 36 months, respectively, among adult patients on ART in Nigeria.77 The retention rate in our study also compares with the estimated average retention rates for sub-Saharan Africa.77,78 Despite the benefits of ART, studies have demonstrated that retention in care among PLHIV in Nigeria is affected by many factors, including non-disclosure of status, lack of social support, cost, travel time to the health facility, and perceived stigma.79-81 Improving retention will require multi-level interventions such as differentiated service delivery, education and behavior reminders, and community/peer support interventions to address these barriers.82-84

The current study also found differences in effect sizes when categorized by participant follow-up time, indicating that research protocols may influence retention data. Retention rates are higher within the first six months and decline over time.77-78 In our meta-analysis, the retention rate was highest in studies with 6-12 months of follow-up. Studies with > 48 months also recorded high retention rates, but no specific reason was identified for this higher rate.

Retention was also lower in adolescents, children, and young adults. Compared with older PLHIV, adolescents, children, and young adults are more likely to experience factors such as stigma, discrimination, and financial barriers that limit retention in care. It is important to note that limited studies have evaluated retention interventions among adolescents, children, and young adults.84-85 Hence, effective interventions to address retention among these vulnerable groups are urgently needed. Among the eligible articles in this study, only two studies were conducted among adult men who had sex with men, and one was conducted among the elderly. There were no studies on female sex workers, and this is another gap that could be filled by future studies.

Furthermore, among the eligible studies included in this meta-analysis, there were no studies focused solely on the states within the Northeast geographical region. Although some states in the region were included in multi-state studies, we were not able to disentangle the data for analysis. This points to a potential disparity in research among PLHIV in this region and should be a focus for further exploration. Regional differences in the retention rates observed in this study may reflect the health-seeking behavior and geographic access to HIV care across the regions.

Additionally, multiple thematically different definitions were identified from the 54 studies, indicating a lack of agreement on the definition of retention in care. This challenge further highlights the fact that retention in HIV care is a complex issue. Although the challenge of multiple definitions is not a new problem,86-88 metrics for measuring retention have included visit consistency, missing visits, gaps in care, and visit adherence.11,12,89,90 The diverse definitions of retention lead to the inability to accurately compare different strategies for improving retention, thus complicating efforts to improve retention programs and subsequent viral suppression. Therefore, we recommend that a standard definition of retention in care should be widely implemented in HIV studies. This will be crucial for ensuring that future research on retention in care can be more easily compared, and thus new interventions for increasing retention could be developed, implemented, and rigorously evaluated.

Before this study, there has been no synthesis of published data examining retention in care among PLHIV on ART in Nigeria. This review is the first to systematically review the literature and produce an estimate of the true retention in care of the population, which will be important for designing retention programs in Nigeria in the future. In addition, we have identified geopolitical zones where research is inadequate, as well as subgroups where retention is sub-optimal.

This study is subject to some limitations. We could not clearly identify the number of people retained for two studies; hence, we documented the proportion as stated by the authors, but we did not include the two papers in the meta-analysis. Secondly, since we did some extrapolation of retention numbers from the LTFU number presented by some studies, some of the extrapolations may not have been 100% accurate. However, we are confident that these extrapolations are close estimates. Third, the varying definitions of retention made it extremely difficult to categorize the papers sufficiently. Finally, the search was conducted in English language only. Despite that there are many other languages spoken in Nigeria, nearly all academic work on HIV in Nigeria is published in English. It is very unlikely that a paper about HIV in the Nigerian population will be published in any language other than English.

Highlights

Retention in care on antiretroviral therapy (ART) in Nigeria from 2005 to 2021 is 72%.

Retention was highest in the Southeast region with 86% retention.

Retention was highest between 6-12 months on ART.

Retention improved from 2005-2010 when it was 62% to 2016-2021 when it was 71%.

Conclusion

Although there has been progress in HIV case identification and enrollment in treatment, optimal retention while on ART is key to achieving viral suppression and ending the HIV epidemic. Our findings lead us to conclude that retention in care while on ART in Nigeria is 72%, with age and regional variations. This calls for targeted interventions to increase retention in care among PLHIV. Moreover, to further the research agenda on retention in care, HIV practitioners and researchers should agree on a universal definition of retention in care to ensure the standardization of study results.

Acknowledgements

The authors would like to thank the Institute for Health Equity and Social Justice Research, Northeastern University, Boston, USA.

Authors’ Contribution

Conceptualization: John O. Olawepo, Echezona E. Ezeanolue.

Data curation: Philip E. Coombs, Katherine O’Brien, Julia Papasodoro, Shubhi Gupta, John O. Olawepo.

Formal analysis: Neha Singh, John O. Olawepo, Katherine O’Brien, Julia Papasodoro.

Funding acquisition: Katherine O’Brien, Julia Papasodoro, John O. Olawepo.

Investigation: John O. Olawepo, Katherine O’Brien, Julia Papasodoro, Shubhi Gupta, Aarushi Bhan.

Methodology: John O. Olawepo, Philip E. Coombs, Babayemi O. Olakunde, Echezona E. Ezeanolue.

Project administration: John O. Olawepo, Katherine O’Brien, Julia Papasodoro.

Resources: John O. Olawepo, Katherine O’Brien, Julia Papasodoro.

Software: Philip E. Coombs.

Supervision: John O. Olawepo.

Validation: John O. Olawepo, Neha Singh, Philip E. Coombs.

Visualization: Katherine O’Brien, Julia Papasodoro, Neha Singh.

Writing–original draft: Katherine O’Brien, Julia Papasodoro, John O. Olawepo.

Writing–review & editing: John O. Olawepo, Katherine O’Brien, Julia Papasodoro, Philip E. Coombs, Neha Singh, Shubhi Gupta, Aarushi Bhan, Babayemi O. Olakunde, Echezona E. Ezeanolue.

Competing Interests

The authors have no conflicts of interest to declare.

Ethical Approval

Ethical approval was not needed for this study since it is a systematic review and meta-analysis.

Funding

Katherine O’Brien and Julia Papasodoro received undergraduate student funding from the PEAK Ascent Award from Northeastern University, Boston, USA.

Supplementary Files

Supplementary file 1 contains Tables S1-S3.
==== Refs
References

1 Chopra NK Ni H Lim V Past present and future status of HIV-AIDS pandemic problem in world Microbiol Infect Dis 2019 3 1 1 6
2 UNAIDS. Global HIV & AIDS Statistics - Fact sheet. UNAIDS; 2022. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed September 20, 2022.
3 UNAIDS. Nigeria. UNAIDS; 2022. Available from: https://www.unaids.org/en/regionscountries/countries/nigeria. Accessed September 20, 2022.
4 National Institutes of Health. HIV Treatment: The Basics. NIH; 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-treatment-basics. Accessed May 28, 2022.
5 Centers for Disease Control and Prevention. Evidence of HIV Treatment and Viral Suppression in Preventing the Sexual Transmission of HIV. CDC; 2022. Available from: https://www.cdc.gov/hiv/risk/art/evidence-of-hiv-treatment.html. Accessed September 20, 2022.
6 Ali JH Yirtaw TG Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in East Shewa zone, Oromiya, Ethiopia, 2018 BMC Infect Dis 2019 19 1 1084 10.1186/s12879-019-4702-z 31881859
7 Ulloa AC Puskas C Yip B Zhang W Stanley C Stone S Retention in care and mortality trends among patients receiving comprehensive care for HIV infection: a retrospective cohort study CMAJ Open 2019 7 2 E236 45 10.9778/cmajo.20180136
8 Teixeira da Silva DS Luz PM Lake JE Cardoso SW Ribeiro S Moreira RI Poor retention in early care increases risk of mortality in a Brazilian HIV-infected clinical cohort AIDS Care 2017 29 2 263 7 10.1080/09540121.2016.1211610 27461407
9 Ahonkhai AA Adeola J Banigbe B Onwuatuelo I Adegoke AB Bassett IV Impact of unplanned care interruption on CD4 response early after ART initiation in a Nigerian cohort J Int Assoc Provid AIDS Care 2017 16 1 98 104 10.1177/2325957416672010 28084189
10 HIV.gov. HIV Care Continuum. HIV.gov; 2022. Available from: https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum. Accessed February 6, 2024.
11 Font H Rollins N Essajee S Becquet R Foster G Mangwiro AZ Retention-in-care in the PMTCT cascade: definitions matter! Analyses from the INSPIRE projects in Malawi, Nigeria and Zimbabwe J Int AIDS Soc 2020 23 10 e25609 10.1002/jia2.25609 33030306
12 Roscoe C, Hachey DM. Retention in HIV Care. National HIV Curriculum; 2023. Available from: https://www.hiv.uw.edu/go/basic-primary-care/retention-care/core-concept/all. Accessed February 6, 2024.
13 World Health Organization. Global HIV Programme. WHO. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/service-delivery-adherence-retention. Accessed February 6, 2023.
14 Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 2021 372 n71 10.1136/bmj.n71 33782057
15 Olawepo J, Espinola Coombs P, Papasodoro J, O’Brien K, Gupta S, Ezeanolue EA. A Systematic Review on Retention in Care Among People Living with HIV (PLHIV) Who Are on Antiretroviral Therapy (ART) in Nigeria. PROSPERO; 2022. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022308484. Accessed February 6, 2024.
16 Espinola Coombs P. Search Strings for “Retention in Care Among People Living with HIV in Nigeria: A Systematic Review”. Northeastern University Library; 2021. Available from: https://repository.library.northeastern.edu/files/neu:0v838204v. Accessed February 6, 2024.
17 Ouzzani M Hammady H Fedorowicz Z Elmagarmid A Rayyan-a web and mobile app for systematic reviews Syst Rev 2016 5 1 210 10.1186/s13643-016-0384-4 27919275
18 Effective Public Health Practice Project. Quality Assessment Tool for Quantitative Studies. McMaster University; 2010. Available from: https://merst.healthsci.mcmaster.ca/ephpp/. Accessed February 6, 2024.
19 Agaba PA Meloni ST Sule HM Agbaji OO Sagay AS Okonkwo P Treatment outcomes among older human immunodeficiency virus-infected adults in Nigeria Open Forum Infect Dis 2017 4 2 ofx031 10.1093/ofid/ofx031 29497627
20 Agaba PA Genberg BL Sagay AS Agbaji OO Meloni ST Dadem NY Retention in differentiated care: multiple measures analysis for a decentralized HIV care and treatment program in North Central Nigeria J AIDS Clin Res 2018 9 2 756 10.4172/2155-6113.1000756 29682399
21 Agbaji OO Abah IO Falang KD Ebonyi AO Musa J Ugoagwu P Treatment discontinuation in adult HIV-infected patients on first-line antiretroviral therapy in Nigeria Curr HIV Res 2015 13 3 184 92 10.2174/1570162x1303150506181945 25986369
22 Agu K Ochei U Oparah A Onoh O Treatment outcomes in patients receiving combination antiretroviral therapy in central hospital, Benin city, Nigeria Trop J Pharm Res 2010 9 1 1 10 10.4314/tjpr.v9i1.52028
23 Ahonkhai AA Banigbe B Adeola J Onwuatuelo I Bassett IV Losina E High rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in Nigeria BMC Infect Dis 2015 15 397 10.1186/s12879-015-1137-z 26424505
24 Ahonkhai AA Banigbe B Adeola J Adegoke AB Regan S Bassett IV Age matters: increased risk of inconsistent HIV care and viremia among adolescents and young adults on antiretroviral therapy in Nigeria J Adolesc Health 2016 59 3 298 304 10.1016/j.jadohealth.2016.05.002 27329680
25 Ahonkhai AA Regan S Idigbe I Adeniyi O Aliyu MH Okonkwo P The impact of user fees on uptake of HIV services and adherence to HIV treatment: findings from a large HIV program in Nigeria PLoS One 2020 15 10 e0238720 10.1371/journal.pone.0238720 33031440
26 Akanbi MO Achenbach CJ Feinglass J Taiwo B Onu A Pho MT Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study AIDS Res Hum Retroviruses 2013 29 6 931 7 10.1089/aid.2012.0231 23316724
27 Aliyu A El-Kamary S Brown J Agins B Ndembi N Aliyu G Performance and trend for quality of service in a large HIV/AIDS treatment program in Nigeria AIDS Res Ther 2019 16 1 29 10.1186/s12981-019-0242-2 31575377
28 Aliyu A Adelekan B Andrew N Ekong E Dapiap S Murtala-Ibrahim F Predictors of loss to follow-up in art experienced patients in Nigeria: a 13-year review (2004-2017) AIDS Res Ther 2019 16 1 30 10.1186/s12981-019-0241-3 31594539
29 Anígilájé EA Dabit OJ Tyovenda RK Emebolu AJ Agbedeh AA Olutola A Effects of leisure activities and psychosocial support on medication adherence and clinic attendance among children on antiretroviral therapy HIV AIDS (Auckl) 2014 6 127 37 10.2147/hiv.s64964 25210476
30 Anigilaje EA Aderibigbe SA Mortality in a cohort of HIV-infected children: a 12-month outcome of antiretroviral therapy in Makurdi, Nigeria Adv Med 2018 2018 6409134 10.1155/2018/6409134 30018988
31 Asieba IO Oqua DA Wutoh AA Agu KA Omeh OI Adeyanju ZA Antiretroviral therapy in community pharmacies - Implementation and outcomes of a differentiated drug delivery model in Nigeria Res Social Adm Pharm 2021 17 5 842 9 10.1016/j.sapharm.2020.06.025 32839146
32 Avong YK Aliyu GG Jatau B Gurumnaan R Danat N Kayode GA Integrating community pharmacy into community based anti-retroviral therapy program: a pilot implementation in Abuja, Nigeria PLoS One 2018 13 1 e0190286 10.1371/journal.pone.0190286 29320531
33 Babatunde O Ojo OJ Atoyebi OA Ekpo DS Ogundana AO Olaniyan TO Seven-year review of retention in HIV care and treatment in federal medical centre Ido-Ekiti Pan Afr Med J 2015 22 139 10.11604/pamj.2015.22.139.4981 26889320
34 Badejo O Noestlinger C Jolayemi T Adeola J Okonkwo P Van Belle S Multilevel modelling and multiple group analysis of disparities in continuity of care and viral suppression among adolescents and youths living with HIV in Nigeria BMJ Glob Health 2020 5 11 e003269 10.1136/bmjgh-2020-003269
35 Chamla DD Asadu C Davies A de Wagt A Ilesanmi O Adeyinka D Patching the gaps towards the 90-90-90 targets: outcomes of Nigerian children receiving antiretroviral treatment who are co-infected with tuberculosis J Int AIDS Soc 2015 18 Suppl 6 20251 10.7448/ias.18.7.20251 26639112
36 Charurat M Oyegunle M Benjamin R Habib A Eze E Ele P Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors PLoS One 2010 5 5 e10584 10.1371/journal.pone.0010584 20485670
37 Charurat ME Emmanuel B Akolo C Keshinro B Nowak RG Kennedy S Uptake of treatment as prevention for HIV and continuum of care among HIV-positive men who have sex with men in Nigeria J Acquir Immune Defic Syndr 2015 68 Suppl 2 S114 23 10.1097/qai.0000000000000439 25723975
38 Chime OH Ndibuagu EO Orji CJ Rates and predictors of adherence and retention for antiretroviral therapy among HIV-positive adults in Enugu, Nigeria Malawi Med J 2019 31 3 202 11 10.4314/mmj.v31i3.7 31839890
39 Coker M Etiebet MA Chang H Awwal G Jumare J Musa BM Socio-demographic and adherence factors associated with viral load suppression in HIV-infected adults initiating therapy in northern Nigeria: a randomized controlled trial of a peer support intervention Curr HIV Res 2015 13 4 279 85 10.2174/1570162x13666150407143838 25845393
40 Dakum P Avong YK Odutola MK Okuma J Kayode GA Nta IE Cohort profile: the Nigerian HIV geriatric cohort study BMC Public Health 2020 20 1 1797 10.1186/s12889-020-09833-9 33243227
41 Dakum P Ajav-Nyior J Attah TA Kayode GA Gomwalk A Omuh H Effect of community antiretroviral therapy on treatment outcomes among stable antiretroviral therapy patients in Nigeria: a quasi-experimental study PLoS One 2021 16 4 e0250345 10.1371/journal.pone.0250345 33901199
42 Dalhatu I Onotu D Odafe S Abiri O Debem H Agolory S Outcomes of Nigeria’s HIV/AIDS treatment program for patients initiated on antiretroviral treatment between 2004-2012 PLoS One 2016 11 11 e0165528 10.1371/journal.pone.0165528 27829033
43 Daniel OJ Oladapo OT Ogundahunsi OA Ogundahunsi S Ogun SA Odusoga OA Default from anti-retroviral treatment programme in Sagamu, Nigeria Afr J Biomed Res 2008 11 2 221 4 10.4314/ajbr.v11i2.50715
44 Dayyab FM Mukhtar F Iliyasu G Habib AG Determinants of loss to follow-up among people living with HIV on antiretroviral therapy in Nigeria Afr J AIDS Res 2021 20 1 93 9 10.2989/16085906.2021.1874444 33685377
45 Dulli L Ridgeway K Packer C Murray KR Mumuni T Plourde KF A social media-based support group for youth living with HIV in Nigeria (SMART Connections): randomized controlled trial J Med Internet Res 2020 22 6 e18343 10.2196/18343 32484444
46 Eguzo KN Lawal AK Umezurike CC Eseigbe CE Predictors of loss to follow-up among HIV-infected patients in a rural south-eastern Nigeria hospital: a 5-year retrospective cohort study Ann Med Health Sci Res 2015 5 6 373 8 10.4103/2141-9248.177988 27057373
47 Holstad MM Essien JE Ekong E Higgins M Teplinskiy I Adewuyi MF Motivational groups support adherence to antiretroviral therapy and use of risk reduction behaviors in HIV positive Nigerian women: a pilot study Afr J Reprod Health 2012 16 3 14 27 23437496
48 Ibiloye O Decroo T Eyona N Eze P Agada P Characteristics and early clinical outcomes of key populations attending comprehensive community-based HIV care: experiences from Nasarawa state, Nigeria PLoS One 2018 13 12 e0209477 10.1371/journal.pone.0209477 30571744
49 Idigbe EO Adewole TA Eisen G Kanki P Odunukwe NN Onwujekwe DI Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program J Acquir Immune Defic Syndr 2005 40 1 65 9 10.1097/01.qai.0000159516.39982.1b 16123684
50 Katbi M Adegboye AA Bello M Gumel AG Adedoyin A Yunusa F Effect of community treatment initiative on antiretroviral therapy uptake among linkage-resistant people living with HIV in northern Nigeria Int J Infect Dis 2019 87 185 92 10.1016/j.ijid.2019.08.014 31446175
51 Meloni ST Chang C Chaplin B Rawizza H Jolayemi O Banigbe B Time-dependent predictors of loss to follow-up in a large HIV treatment cohort in Nigeria Open Forum Infect Dis 2014 1 2 ofu055 10.1093/ofid/ofu055 25734125
52 Meloni ST Chaplin B Chang C Rawizza H Okonkwo P Kanki PJ Patterns of adherence and loss to follow-up in pediatric patients on ART in Nigeria Curr HIV Res 2015 13 3 210 8 10.2174/1570162x1303150506183921 25986372
53 Meloni ST Chang CA Eisen G Jolayemi T Banigbe B Okonkwo PI Long-term outcomes on antiretroviral therapy in a large scale-up program in Nigeria PLoS One 2016 11 10 e0164030 10.1371/journal.pone.0164030 27764094
54 Meloni ST Agaba P Chang CA Yiltok E Oguche S Ejeliogu E Longitudinal evaluation of adherence, retention, and transition patterns of adolescents living with HIV in Nigeria PLoS One 2020 15 7 e0236801 10.1371/journal.pone.0236801 32735566
55 Musa BM Coker M Bussell S Aliyu M Babashani M Muhammad H Long-term outcomes of antiretroviral therapy in an adult HIV program: a 10-year retrospective cohort study in Kano, Nigeria Ann Saudi Med 2015 35 4 303 11 10.5144/0256-4947.2015.303 26497711
56 Odafe S Idoko O Badru T Aiyenigba B Suzuki C Khamofu H Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals J Int AIDS Soc 2012 15 2 17424 10.7448/ias.15.2.17424 23010378
57 Odafe S Torpey K Khamofu H Ogbanufe O Oladele EA Kuti O The pattern of attrition from an antiretroviral treatment program in Nigeria PLoS One 2012 7 12 e51254 10.1371/journal.pone.0051254 23272094
58 Ojeniran MA Emokpae A Mabogunje C Akintan P Hoshen M Weiss R How are children with HIV faring in Nigeria? A 7-year retrospective study of children enrolled in HIV care BMC Pediatr 2015 15 87 10.1186/s12887-015-0405-9 26198439
59 Ojikutu B Higgins-Biddle M Greeson D Phelps BR Amzel A Okechukwu E The association between quality of HIV care, loss to follow-up and mortality in pediatric and adolescent patients receiving antiretroviral therapy in Nigeria PLoS One 2014 9 7 e100039 10.1371/journal.pone.0100039 25075742
60 Okafor I Ugwu E Obi S Odugu B Virtual elimination of mother-to-child transmission of human immunodeficiency virus in mothers on highly active antiretroviral therapy in Enugu, south-eastern Nigeria Ann Med Health Sci Res 2014 4 4 615 8 10.4103/2141-9248.139344 25221715
61 Okwuraiwe AP Audu RA Ige FA Salu OB Onwuamah CK Musa AZ Long term outcomes of highly active antiretroviral therapy in HIV infected Nigerians and those co-infected with hepatitis B and C viruses Afr J Clin Exp Microbiol 2021 22 1 67 73 10.4314/ajcem.v22i1.9
62 Oladimeji O Isaakidis P Obasanya OJ Eltayeb O Khogali M Van den Bergh R Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria PLoS One 2014 9 4 e94393 10.1371/journal.pone.0094393 24722139
63 Onoka CA Uzochukwu BS Onwujekwe OE Chukwuka C Ilozumba J Onyedum C Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria Pathog Glob Health 2012 106 1 46 54 10.1179/2047773211y.0000000018 22595274
64 Oyeledun B Phillips A Oronsaye F Alo OD Shaffer N Osibo B The effect of a continuous quality improvement intervention on retention-in-care at 6 months postpartum in a PMTCT program in northern Nigeria: results of a cluster randomized controlled study J Acquir Immune Defic Syndr 2017 75 Suppl 2 S156 64 10.1097/qai.0000000000001363 28498185
65 Ramadhani HO Ndembi N Nowak RG Ononaku U Gwamna J Orazulike I Individual and network factors associated with HIV care continuum outcomes among Nigerian MSM accessing health care services J Acquir Immune Defic Syndr 2018 79 1 e7 16 10.1097/qai.0000000000001756 29781881
66 Rawizza HE Chang CA Chaplin B Ahmed IA Meloni ST Oyebode T Loss to follow-up within the prevention of mother-to-child transmission care cascade in a large ART program in Nigeria Curr HIV Res 2015 13 3 201 9 10.2174/1570162x1303150506183256 25986371
67 Sam-Agudu NA Ramadhani HO Isah C Anaba U Erekaha S Fan-Osuala C The impact of structured mentor mother programs on 6-month postpartum retention and viral suppression among HIV-positive women in rural Nigeria: a prospective paired cohort study J Acquir Immune Defic Syndr 2017 75 Suppl 2 S173 81 10.1097/qai.0000000000001346 28498187
68 Stafford KA Odafe SF Lo J Ibrahim R Ehoche A Niyang M Evaluation of the clinical outcomes of the test and treat strategy to implement treat all in Nigeria: results from the Nigeria Multi-Center ART Study PLoS One 2019 14 7 e0218555 10.1371/journal.pone.0218555 31291273
69 Taiwo BO Kuti KM Kuhns LM Omigbodun O Awolude O Adetunji A Effect of text messaging plus peer navigation on viral suppression among youth with HIV in the iCARE Nigeria pilot study J Acquir Immune Defic Syndr 2021 87 4 1086 92 10.1097/qai.0000000000002694 34153015
70 Ugbena R Aberle-Grasse J Diallo K Bassey O Jelpe T Rottinghaus E Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria Clin Infect Dis 2012 54 Suppl 4 S375 80 10.1093/cid/cir1064 22544206
71 Ugoji C Okere N Dakum P Ake-Uzoigwe R Igboelina D Ndembi N Correlates of patient retention in HIV care and treatment programs in Nigeria Curr HIV Res 2015 13 4 300 7 10.2174/1570162x13999150317155348 25777516
72 Umeokonkwo CD Onoka CA Agu PA Ossai EN Balogun MS Ogbonnaya LU Retention in care and adherence to HIV and AIDS treatment in Anambra State Nigeria BMC Infect Dis 2019 19 1 654 10.1186/s12879-019-4293-8 31331280
73 UNAIDS. Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030. UNAIDS; 2015. Available from: https://www.unaids.org/en/resources/documents/2015/201506_JC2743_Understanding_FastTrack. Accessed February 6, 2024.
74 Gillies K Kearney A Keenan C Treweek S Hudson J Brueton VC Strategies to improve retention in randomised trials Cochrane Database Syst Rev 2021 3 3 MR000032 10.1002/14651858.MR000032.pub3 33675536
75 Higa DH Crepaz N Mullins MM Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996-2014 AIDS Behav 2016 20 5 951 66 10.1007/s10461-015-1204-x 26404014
76 Ehrenkranz P Rosen S Boulle A Eaton JW Ford N Fox MP The revolving door of HIV care: revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals PLoS Med 2021 18 5 e1003651 10.1371/journal.pmed.1003651 34029346
77 Fox MP Rosen S Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008-2013 J Acquir Immune Defic Syndr 2015 69 1 98 108 10.1097/qai.0000000000000553 25942461
78 Fox MP Rosen S Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review Trop Med Int Health 2010 15 Suppl 1 1 15 10.1111/j.1365-3156.2010.02508.x
79 Odediran OO Odukoya OO Balogun MR Colasanti JA Akanmu AS A qualitative study exploring factors associated with retention in HIV care among women with HIV in a large HIV clinic in Lagos, Nigeria, after Implementing the test and treat policy AIDS Res Treat 2022 2022 9074844 10.1155/2022/9074844 35983188
80 Ware NC Wyatt MA Geng EH Kaaya SF Agbaji OO Muyindike WR Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study PLoS Med 2013 10 1 e1001369 10.1371/journal.pmed.1001369 23341753
81 Tebu O Tobin-West C Barriers and facilitators of retention in HIV care among patients attending antiretroviral clinic in UPTH: a qualitative study J Epidemiol Soc Niger 2021 1 10 1 10.5281/zenodo.6555774
82 Pugh LE Roberts JS Viswasam N Hahn E Ryan S Turpin G Systematic review of interventions aimed at improving HIV adherence to care in low- and middle-income countries in sub-Saharan Africa J Infect Public Health 2022 15 10 1053 60 10.1016/j.jiph.2022.08.012 36063721
83 Muhula S Gachohi J Kombe Y Karanja S Interventions to improve early retention of patients in antiretroviral therapy programmes in sub-Saharan Africa: a systematic review PLoS One 2022 17 2 e0263663 10.1371/journal.pone.0263663 35139118
84 Murray KR Dulli LS Ridgeway K Dal Santo L Darrow de Mora D Olsen P Improving retention in HIV care among adolescents and adults in low- and middle-income countries: a systematic review of the literature PLoS One 2017 12 9 e0184879 10.1371/journal.pone.0184879 28961253
85 Casale M Carlqvist A Cluver L Recent interventions to improve retention in HIV care and adherence to antiretroviral treatment among adolescents and youth: a systematic review AIDS Patient Care STDS 2019 33 6 237 52 10.1089/apc.2018.0320 31166783
86 Wheatley MM Knowlton GS Butler M Enns EA Cost-effectiveness of HIV retention and re-engagement interventions in high-income countries: a systematic literature review AIDS Behav 2022 26 7 2159 68 10.1007/s10461-021-03561-w 35076798
87 Mayasi N Situakibanza H Mbula M Longokolo M Maes N Bepouka B Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the ‘treat-all’ strategy PLOS Glob Public Health 2022 2 3 e0000259 10.1371/journal.pgph.0000259 36962315
88 Mugenyi L Nanfuka M Byawaka J Agaba C Mijumbi A Kagimu D Effect of universal test and treat on retention and mortality among people living with HIV-infection in Uganda: an interrupted time series analysis PLoS One 2022 17 5 e0268226 10.1371/journal.pone.0268226 35580126
89 Muwanguzi M Lugobe HM Ssemwanga E Lule AP Atwiine E Kirabira V Retention in HIV care and associated factors among youths aged 15-24 years in rural southwestern Uganda BMC Public Health 2021 21 1 1489 10.1186/s12889-021-11547-5 34332556
90 Afolaranmi TO Hassan ZI Ugwu OJ Ofakunrin AOD Bello KK Chingle MP Retention in HIV care and its predictors among HIV-infected men who have sex with men in Plateau state, North Central Nigeria J Family Med Prim Care 2021 10 4 1596 601 10.4103/jfmpc.jfmpc_1748_20 34123898
